
    
      This is a Phase 1, open-label, uncontrolled, dose-escalation study with dose-expansion at
      doses determined to be tolerated. Patients who tolerate the drug and do not progress will be
      allowed to continue treatment. The study endpoints are safety and tolerability and
      pharmacokinetics. PSA values will also be collected to look for PSA response.
    
  